One of a Kind

How Innovative Farmers are Tailoring Their Crop Protection

LEARN MORE
Man stands in front of a tractor with lines resembling a thumbprint over him
News from Bayer
June 27, 2025
Not intended for U.S. and UK Media
Eylea™ 8 mg with extended 6-month treatment interval approved in the EU
June 03, 2025
Not intended for U.S. and UK Media
U.S. FDA approves third indication of Bayer blockbuster Nubeqa™ (darolutamide) for patients with advanced prostate cancer
June 02, 2025
Not intended for UK Media – Data from Phase III OASIS-4 study to be presented for the first time at 2025 ASCO Annual Meeting:
Elinzanetant significantly reduces frequency of moderate to severe vasomotor symptoms associated with endocrine therapy for breast cancer in Phase III OASIS-4 study